Cue Biopharma receives Nasdaq deficiency notice for bid price below $1.00

Cue Biopharma, Inc.

Received Nasdaq notice on August 15, 2024 for failure to meet minimum bid price of $1.00 for 30 consecutive business days.
Has 180 calendar days (until Feb 11, 2025) to regain compliance by having bid price ≥$1.00 for 10 consecutive business days.
If not compliant, may qualify for another 180-day period, subject to meeting other listing standards.
Company will evaluate options including potential reverse stock split to cure deficiency.
No assurance of regaining compliance; stock remains listed pending cure or potential delisting appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.